Following the publication of the Review: Clinical Trial Outcomes article by Thomas A Burrow and Gregory A Grabowski entitled 'Velaglucerase alfa in the treatment of Gaucher disease type 1', in the February 2011 issue of *Clinical Investigation* (*Clin. Invest.* 1[2], 285–293 [2011]), it has been brought to our attention that:

Table 1 on page 288 was incorrectly printed as:

Table 1. Therapeutic goals for Gaucher disease.

Parameter	Goal	
	Short term (1–2 years)	Long term (2–5 years)
Anemia		
■ Children ≤12 years	≥11.0 g/dl	Maintain improved hemoglobin achieved after first 1–2 years
■ Females >12 years	≥11.0 g/dl	
■ Males >12 years	≥12.0 g/dl	
Platelets		
■ Splenectomized patients	Normalization by 1 year of treatment	Maintain normalized platelets achieved after first year
■ Moderate baseline thrombocytopenia (60–120 × 10^9/l)	Increased platelets by 1.5–2.0-fold by year 1	Platelets approaching low–normal by year 2
■ Severe baseline thrombocytopenia (<60 × 10^9/l)	Increased platelet count by 1.5-fold by year 1	Continue to improve platelet count slightly (doubling by year 2)
Liver volume	20–30% reduction in liver volume or reduce/maintain liver volume 1.0–1.5 × normal	40–40% reduction in liver volume or reduce/maintain liver volume 1.0–1.5 × normal
Spleen volume	30–50% reduction in spleen volume	50–60% reduction in spleen volume or reduce/maintain spleen volume ≤2–8 × normal
Skeletal pathology	Lessen or eliminate bone pain/crises	Improved bone mineral density

Adapted from [12,13].

This should have read:

Table 1. Therapeutic goals for Gaucher disease.

Parameter	Goal	
	Short term (1–2 years)	Long term (2–5 years)
Anemia		
■ Children ≤12 years	≥11.0 g/dl	Maintain improved hemoglobin achieved after first 1–2 years
■ Females >12 years	≥11.0 g/dl	
■ Males >12 years	≥12.0 g/dl	
Platelets		
■ Splenectomized patients	Normalization by 1 year of treatment	Maintain normalized platelets achieved after first year
■ Moderate baseline thrombocytopenia (60–120 × 10^9/l)	Increased platelets by 1.5–2.0-fold by year 1	Platelets approaching low–normal by year 2
■ Severe baseline thrombocytopenia (<60 × 10^9/l)	Increased platelet count by 1.5-fold by year 1	Continue to improve platelet count slightly (doubling by year 2)
Liver volume	20–30% reduction in liver volume or reduce/maintain liver volume 1.0–1.5 × normal	30–40% reduction in liver volume or reduce/maintain liver volume 1.0–1.5 × normal
Spleen volume	30–50% reduction in spleen volume	50–60% reduction in spleen volume or reduce/maintain spleen volume ≤2–8 × normal
Skeletal pathology	Lessen or eliminate bone pain/crises	Improved bone mineral density

Adapted from [12,13].

The authors and editors of *Clinical Investigation* would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.